DEA Decision to Remove Some Cannabidiol from Most Restrictive Class of Controlled Substances May Have Far-Reaching Impact on the CBD Market
The U.S. Drug Enforcement Administration (DEA) ruling enables physicians to prescribe Epidiolex, a non-synthetic cannabis-derived medicine from United Kingdom-grown cannabis Cannabis entrepreneurs applaud the decision, even though it only applies to that specific drug; DEA decision requires approval of medications by the U.S. Food & Drug Administration (FDA) Several other CBD medications are in the pipeline for consideration by the FDA; move is seen as legitimizing the industry and changing it to traditional distribution of prescription-to-drug store The DEA decision to approve the first non-synthetic CBD-derived drug, Epidiolex, and remove it from the agency’s most restrictive class of controlled substances…

















